CN104220050A - Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same - Google Patents

Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same Download PDF

Info

Publication number
CN104220050A
CN104220050A CN201380019865.6A CN201380019865A CN104220050A CN 104220050 A CN104220050 A CN 104220050A CN 201380019865 A CN201380019865 A CN 201380019865A CN 104220050 A CN104220050 A CN 104220050A
Authority
CN
China
Prior art keywords
hard capsule
tablet
compound formulation
capsule
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380019865.6A
Other languages
Chinese (zh)
Inventor
金京洙
金东胡
权宅灌
金用镒
朴宰贤
禹钟守
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49327885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104220050(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Priority to CN201910062530.1A priority Critical patent/CN110051642B/en
Publication of CN104220050A publication Critical patent/CN104220050A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided is a composite formulation comprising multi-unit spheroidal tablets (MUSTs) encapsulated in a hard capsule and a method for preparing same. The inventive hard capsule composite formulation can effectively charge the MUSTs in the limited space of the capsule, which allows charging a high dose of different pharmaceutically active ingredients in a capsule with a relatively small size, to thereby increase the productivity and render it readily administered to patients. Also, the capsule has a good dissolution rate because the pharmaceutically active ingredients contained in the capsule are separated from one another; therefore, the dissolution rates of the ingredients are less affected by one another. It may also be possible to maximize the therapeutic effects of the pharmaceutically active ingredients since the composite formulation has good stability.

Description

Comprise compound formulation of the spherical tablet (MUST) of the multiple-unit be encapsulated in hard capsule and preparation method thereof
Technical field
The present invention relates to hard capsule compound formulation containing multiple-unit (many units, multi-unit) spherical (near-spherical, spheroidal) tablet (MUST) and preparation method thereof.
Background technology
Progress in field of medicaments improves quality of life, and adds the life expectancy of people.But, in treatment effect suffered from the patient of medical conditions, one definite limitation is also had for single active constituents of medicine.Therefore, generally for cooperative effect and simultaneously or according to the order of sequence administration can have the multi-medicament of the different mechanism of action (pattern).
But the administering drug combinations of two or more separate medical unit (unit, unit) perhaps can reduce the compliance of patient consumes, thus causes great inconvenience to the patient standing continuous Drug therapy.In addition, patient has to once take this multiple drug unit, and is carried always with oneself.This brings great inconvenience at its daily life also can to patient.
In order to adjust these problems, people have proposed the method for many drug pack in single bag.Such as, Torrent Pharmaceuticals Ltd. (India) has issued a kind of compound formulation " CVpill ", a kind of single test kit containing capsule and tablet being used for the treatment of cardiovascular disease.CVpill is by containing the atorvastatin of 10mg powder type, and the ramipril of powder type and the capsule of 75mg Enteric coatings aspirin tablet and the slow releasing tablet containing 50mg metoprolol are formed.Carry-on capsule and tablet must administrations simultaneously once a day.But this assembly packaging product comprising simple test kit almost can not improve the compliance of patient consumes, but this perhaps sought in compound formulation.Therefore, the demand for the research of " composition of medicine or the compound formulation " of exploitation given activity composition constantly increases.
Term " compound formulation " as used herein refers to the combination of two kinds or multiple different activities composition or medicine at single dosage unit as the combination in tablet or capsule.But, for the compound formulation of given activity composition exploitation due to following reason be very difficult sometimes.
First, the combination of the given activity composition used for compound formulation should be easy to carry out.And the compositions containing active component and pharmaceutical excipient should have suitable size and weight for its administration.But, always do not develop the compound formulation met this requirement easily.If the medicament contg used is excessive or not enough, then the weight of compositions is adjusted to suitable level by being difficult to by this.In addition, beyond thought problem may be accidental in the process of the various conditions of process caused by the pharmacokinetics of medicine and medicinal property.
Secondly, the chemical interaction in compound formulation between active component is being prepared and may reduce the stability of medicine.Especially, if when its stability perhaps reduces due to chemical interaction when it combines, be then more difficult to the fixed Combination dosage form developing the enough physical and chemical stabilities had drug regimen.
When preparing the compound formulation of tablet, double-deck or three layers of pelleter can be used in separate active ingredients.In addition, not only this method needs special equipment, and the main component in mechanically also can not being separated every layer completely, because undesirable reaction may betide on the interface of these layers.
For capsule (capsule, capsule), the medicine of conventional hard capsule meeting powder filler, granule or pellet form.And, only have single-activity composition to be filled in hard capsule by single filling step.In addition, the density of the density ratio tablet that the medicine of powder, granule or pellet form has is low because the former and without undergoing high pressure pressing step.Therefore, there is restriction in the medication amount being filled into the powder in capsule, granule or pellet form.In order to fill a kind of active component of high dose or more than a kind of active component, the size of capsule must increase, and could hold medicines a large amount of like this in single hard capsule.But, if the size of capsule becomes excessive to hold a large amount of medicines, then may cause being difficult to swallow, dysphagia.Specifically, the difficulty that large-sized capsule with No.00 (8.5mm capsule cap diameter and 23.3mm capsule length) and No.0 (7.6mm capsule cap diameter and 21.7mm capsule length) may cause old man or child to be swallowed.This also may be carried inconvenience due to its large scale.
Therefore, the present inventor makes great efforts the shortcoming solving compound formulation, and has developed a kind of a small amount of containing often kind of main constituent, such as, and the hard capsule of 1 to 3 tablet.But the initial dissolution rate (in 15 minutes) of hard capsule slows down due to the delay of the disintegration time of described hard capsule, and the deviation observed between each dissolving test result increases.Therefore, if containing the medicine needing quick absorption rate, such as, the maximum drug concentration time (T of 1 ~ 2h maximum), then may be difficult to the identical bioequivalence from compound formulation expection single dose form.Therefore, still need to develop and a kind ofly there is good productivity and stability and the preparation that do not have that initial dissolution rate postpones.
Summary of the invention
Therefore, an object of the present invention is to provide one and there is in 15 minutes initial dissolution rate without delay, and due to the little good body absorption rate shown of each rate of dissolution change, and the compound formulation of good productivity ratio and stability.
Another object of the present invention is to provide the method for the preparation of compound formulation.
According to one object of the present invention, provide a kind of hard capsule compound formulation comprising two or more active constituents of medicine, wherein each active constituents of medicine to be contained in the spherical tablet of multiple-unit (MUST) and multiple MUST of often kind of active constituents of medicine are packaged in hard capsule.
According to another object of the present invention, provide a kind of method for the preparation of hard capsule compound formulation, it comprises the following steps: (1) preparation comprises the MUST of active constituents of medicine; (2) multiple MUST is encapsulated in hard capsule makes hard capsule compound formulation comprise two or more active constituents of medicine.
Can effectively MUST be filled in the capsule of the confined space according to the hard capsule compound formulation that the present invention comprises the spherical tablet of multiple-unit (MUST), this allows the different pharmaceutical active component of filling high dose in the capsule with relative small size, thus boosts productivity and make it be easy to deliver medicine to patient.Capsule has excellent dissolution speed, is because the active constituents of medicine be contained in capsule is be separated each other; Therefore, the rate of dissolution of these compositions affects not quite each other.This also can maximize the curative effect of active constituents of medicine, because compound formulation has good stability.
Accompanying drawing explanation
Fig. 1 shows the schematic diagram of the hard capsule compound formulation according to one embodiment of the present invention.
Fig. 2 shows the schematic diagram of the spherical tablet of multiple-unit (MUST) be filled in hard capsule compound formulation.
Fig. 3 and Fig. 4 is the curve chart showing montelukast and levocetirizine rate of dissolution (dissolution rate, dissolution rate) according to testing example 1 respectively.
Fig. 5 is the curve chart showing ambroxol rate of dissolution according to testing example 2.
Fig. 6 and 7 is the curve chart showing montelukast and levocetirizine blood plasma level according to testing example 3 respectively.
Detailed description of the invention
Below embodiments of the present invention are described in detail.
The invention provides the hard capsule compound formulation that one comprises the spherical tablet of multiple-unit (MUST).The schematic diagram according to hard capsule compound formulation of the present invention is shown in Fig. 1.
Term " compound formulation " refers to the combination of two or more different activities compositions or medicine in single unit dose as used herein.Compound formulation of the present invention comprises capsule, and multiple multiple-unit minipill, and it comprises arbitrary active constituents of medicine, has the class spherical form be encapsulated in capsule.
In compound formulation of the present invention, capsule can be any routine encapsulation used in pharmaceuticals industry, preferred hard capsule.Hard capsule is made up of capsule body and cap (cap), so makes Contents Fill in the inner space of capsule body, and capsule cap is used for the use of closed capsule body.In fact deliver medicine to the final capsule product of patient, close with its cap seal, there is the shape of the cylinder with domed ends, and content-filled in the inner space of capsule body.In the ordinary course of things, the general frequent powder filler in inner space of conventional capsules, granule or pill, but the inner space of contrary compound formulation of the present invention is characterised in that filling micro tablet.The size of micro tablet is less, and therefore multiple micro tablet, such as, 4 or more, can be filled in the inner space of compound formulation of the present invention.
The capsule with various sizes numbering uses according to the size of capsule, but has the difficulty that the capsule of large scale as No. 00 (8.5mm capsule cap diameter and 23.3mm capsule length) may cause old man or child to swallow it.Due to its large scale it also may not Portable belt.
Therefore, the size of compound formulation capsule of the present invention is preferably hard capsule No. 0 or less, such as, No. 0, hard capsule (7.6mm capsule cap diameter and 21.7mm capsule length), No. 1, hard capsule (6.9mm capsule cap diameter and 19.1mm capsule length), No. 2, hard capsule (6.4mm capsule cap diameter and 17.6mm capsule length), No. 3, hard capsule (5.8mm capsule cap diameter and 15.7mm capsule length) or No. 4, hard capsule (5.3mm capsule cap diameter and 14.2mm capsule length), and more preferably hard capsule No. 1 or less.
In compound formulation of the present invention, MUST can comprise active constituents of medicine and medical additive.
MUST can by adopting the pressing step of tablet machine to be prepared in the mixture of active constituents of medicine and medical additive or granule experience.In this case, the hardness of tablet is determined by the size of pressing pressure.
Tablet can be prepared into the form of circle, rectangle or ellipse, but circular form is preferred, because it allows more easily to be packaged in the inner space of hard capsule.Specifically, when the diameter of circular tablet is similar to the thickness of circular tablet, it has spherical form, which improves the flowable of tablet, and also minimizes by the packaging arrangement needed for formation the space formed in capsule.
Therefore, the tablet that be filled in capsule is preferred in a circular form, more preferably miniature spherical tablet (MUST).Be contained in the spherical tablet of multiple-unit in compound formulation of the present invention as shown in Figure 2.
In order to prepare the circular tablet of spherical form, the circular tablet diameter of each MUST and the ratio of its thickness need to be in 1:0.7 to 1:1.3, in the scope of preferred 1:0.8 to 1:1.2.The MUST according to the present invention with circular tablet diameter in 1:0.7 to 1:1.3 scope and its thickness ratio can the inner space of filled hard capsules completely, and do not form any space, therefore, the pharmaceutical composition that consumption is larger even can be filled in less capsule.
In addition, when the cylinder height of MUST is in particular range with the ratio of gross thickness, the tabletting characteristics of MUST is improved, and this can improve the speed in tablet forming technique process.
Specifically, the total length that cylinder height equals tablet deducts the length that two domed ends (top and bottom) merge, as shown in Figure 2.If the ratio of cylinder height is too high in gross thickness, then tablet can form rectangular shape, and this may make the mobility of tablet be deteriorated, and during technology of the package process, causes trouble thus.If when in gross thickness, the ratio of cylinder height is too low, tablet can tend in tablet forming technique process broken.Therefore, be 1:0.3 to 1:0.9 according to the thickness of MUST of the present invention and the ratio scope of cylinder height, preferred 1:0.5 to 1:0.8.
In addition, MUST has undersized micro tablet, and the inner space of capsule comprises at least 4 or more micro tablets thus, and preferably 4 to 40 MUST/ often plant active constituents of medicine.
Therefore, be less than the internal diameter of hard capsule main body at the diameter of the MUST of compound formulation according to the present invention, and be preferably less than or equal to 1/2 of hard capsule internal diameter.
If MUST diameter is excessive (such as, be greater than 1/2 of hard capsule inner major diameter), these tablets are then just difficult to be filled in the inner space of capsule, and the tablet sum being filled to capsule space can reduce simultaneously, thus suppress the reduction of the raising of rate of dissolution or the standard deviation of rate of dissolution.Even if tablet after filling, do not allow the filling arrangement project organization needed for being formed yet, and cause thus forming space in capsule.On the other hand, when MUST diameter too small (such as, being less than 1mm), the amount of filling in single tablet is limited, and the physical property of tablet also may be subject to environmental variable impact to a great extent during tablet forming technique process.
Therefore, it is 1 to 4mm that MUST according to the present invention has scope, and preferable range is the diameter of 1.5 to 3mm.If the diameter of tablet is in scope, then desired filling arrangement design just can realize, and this allows to maximize the content will filled in capsule, and this also produces the improvement of rate of dissolution owing to having multiple tablet.
Compared to the conventional hard capsule of filling with granule or pill, compound formulation of the present invention has good pack completeness.
The filling rate of capsule can be calculated by the weight of the raw material be filled in capsule in the volume of capsule body.Such as, when 150mg compositions is filled in No. 2 capsules (volume: 0.37mL), filling rate is about 0.41g/mL.Generally speaking, if filler particles or pellet material, be then difficult to reach the filling rate of 0.6g/mL or larger because packing material concentration is low or there is space in pill.In contrast, compound formulation according to the present invention has the filling rate of 0.6g/mL to 1.0mg/mL, and therefore has the filling rate of 0.6mg/mL or larger, and this makes it the size likely reducing hard capsule, makes it be easy to deliver medicine to patient.
In addition, compound formulation according to the present invention fills compared to tradition that to have diameter be that the routine encapsulation of the typical tablet of 5mm or larger has significantly lower porosity (absolutely empty rate) (the rate of empty space).Owing to there is inverse relation between filling rate and porosity value, then MUST of the present invention can be filled in the inner space of capsule with optimum level.
According to an aspect of the present invention, provide and a kind ofly comprise multiple diameter and be less than or equal to 1/2 of ebonite utricule internal diameter and scope is the hard capsule compound formulation of the MUST of 1mm to 4mm.In these formulations, the diameter of MUST can be in the scope of 1.5mm to 3mm.
According to a further aspect of the present invention, provide a kind of multiple thickness and cylinder height ratio ranges of comprising and be 1:0.7 to 1:1.3 and its diameter range is the hard capsule compound formulation of the MUST of 1mm to 4mm.In these formulations, the thickness/cylinder height ratio of MUST can be in the scope of 1:0.8 to 1:1.2, and its diameter can be in the scope of 1.5mm to 3mm.
According to a further aspect in the invention, provide and a kind ofly comprise that multiple diameter is less than or equal to the MUST of 1/2 of ebonite utricule internal diameter and the thickness of MUST is in the hard capsule compound formulation in 1:0.8 to 1:1.2 scope with the ratio of cylinder height.
Two or more medicines as known in the art any can both be used as the active component of MUST of the present invention.The medicine used in the present invention can be selected from identical or different medicine group.The example of adoptable medicine comprises antipyretic, analgesics, antiinflammatory and muscle relaxant as tramadol, naproxen, ibuprofen, (S)-ibuprofen, aspirin, acetaminophen, indomethacin, diclofenac sodium, aceclofenac, ketoprofen, isopropylantipyrine, Phenacetin, flurbiprofen, Phenylbutazone, etodolac, celecoxib, etoricoxib, eperisone and pharmaceutical salts thereof; Antiulcerative is as omeprazole, esomeprazole, pantoprazole, cimetidine, famotidine, ranitidine, nizatidine, roxatidine and pharmaceutical salts thereof; Cardiovascular drug or vasodilator are as losartan, Irb (ibesartan), Candesartan, telmisartan, valsartan, nifedipine, amlodipine, verapamil, captopril, diltiazem hydrochloride, Propranolol, oxprenolol, nitroglycerin, enalapril and pharmaceutical salts thereof; Antidiabetic drug, as metformin, glimepiride, sitagliptin, rosiglitazone, pioglitazone and pharmaceutical salts thereof; Lipidemia agent is as simvastatin, Rosuvastatin, atorvastatin and pharmaceutical salts thereof; Antibiotic is as ampicillin, amoxicillin, cefalexin, cefuroxime, cefdinir, cefadroxil, cefprozil, cefpodoxime, cefditoren, cefaclor, cefixime, cefradine, Loracarbef, ceftibuten, cefatrizine, cefcapene, erythromycin, Tetracyclines, quinolones and pharmaceutical salts thereof; Antitussive or antasthmatic are if montelukast, theophylline, aminophylline, codeine phosphate, hydrochloride methyl ephedrine, dextrorotation methorphan, narcotine, salbutamol, ambroxol, levodropropizine, clenobuterol hydrochloride, terbutaline and pharmaceutical salts thereof, antiemetic or GIT regulator are as ondansetron, metoclopramide, domperidone, Trimebutine Maleate, cisapride, left-handed sulpiride and pharmaceutical salts thereof; Alibra thing is as sldenafil, Vardenafil, tadanafil, udenafil and pharmaceutical salts thereof; And dementia medicine is as bright, acetyl-L-carnitine, memantine, xaliproden and the pharmaceutical salts thereof of donepezil, galantamine, Li Fansi.
In addition, anti-BPH medicine is as Tamsulosin; Antimigraine is as Zomitriptan and rizatriptan; Psychoanaleptics; Antimicrobial; Hydryllin is as cetirizine, levocetirizine and loratadine; Antidiabetic drug; Anti-allergic drug; Contraceptive; Vitimin supplement; Anticoagulant is as clopidogrel; Muscle relaxant; Cerebral metabolism reinforcing agent; Diuretic is as torasemide and furosemide; Anti-epileptics as gabapentin, lyrica, valproic acid, topiramate, carbamazepine, lamotrigine, oxcarbazepine; With Mirapexin as selegiline; Antipsychotic drug, as risperidone, Ziprasidone, Quetiapine, olanzapine, clozapine and Paliperidone and pharmaceutical salts thereof, also may be used in the present invention.In addition, biological preparation such as oral vaccine may be used in the present invention.
Preferred active component can be selected from the group be made up of levocetirizine, montelukast, ambroxol, levodropropizine, losartan, Ai Baishatan, amlodipine, Rosuvastatin, atorvastatin, aspirin, clopidogrel, aceclofenac, eperisone, esomeprazole, naproxen and pharmaceutical salts thereof.
In compound formulation of the present invention, MUST can comprise further be selected from by medicinal diluent, disintegrating agent, binding agent, stabilizing agent, lubricant, coloring agent, and composition thereof the medical additive in the group that forms.
Diluent can be selected from by microcrystalline Cellulose, lactose, mannitol, dalcium biphosphate, starch, low-substituted hydroxypropyl cellulose, and composition thereof composition group.The consumption of diluent can be about 1wt% to 99wt% based on tablet total weight amount, preferably about 5wt% to 90wt%.
Disintegrating agent can be any material swelling in liquid environment safety, and it is selected from the group be made up of crospovidone, sodium starch glycollate, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, starch, alginate or its sodium salt or its mixture.In a preferred embodiment of the present invention, disintegrating agent be selected from by low-substituted hydroxypropyl cellulose, crospovidone, sodium starch glycollate, cross-linking sodium carboxymethyl cellulose, and composition thereof the group that forms.The consumption of disintegrating agent can be about 1wt% to 30wt%, preferably about 2wt% to 15wt% based on tablet total weight amount.
Binding agent can be selected from by hydroxypropyl cellulose, hydroxypropyl emthylcellulose, polyvinyl pyrrolidone, copolyvidone, Polyethylene Glycol, light anhydrous silicic acid, synthetic aluminium silicate, silicate derivative as calcium silicates or metasilicic acid magnesium aluminate, phosphate as calcium hydrogen phosphate, carbonate as calcium carbonate, and composition thereof the group that forms, and the amount of the binding agent adopted can be about 1wt% to 30wt%, preferably about 2wt% to 15wt% based on tablet total weight amount.
Stabilizing agent can be antioxidant, acidulant or basifier.
The instantiation of antioxidant comprise butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA) (BHA), ascorbic acid, ascorbic palmitate, ethylenediaminetetraacetic acid (EDTA), sodium pyrosulfite, and composition thereof; Particularly butylated hydroxytoluene is preferred.The object lesson of acidulant comprises organic acid as fumaric acid, citric acid, tartaric acid, succinic acid, lactic acid, malic acid, toluenesulfonic acid, oxalic acid, ascorbic acid, glutamic acid, alginic acid, maleic acid, adipic acid etc.; Mineral acid example hydrochloric acid, sulphuric acid, nitric acid, phosphoric acid, acetic acid, boric acid etc., and composition thereof, preferred fumaric acid, citric acid, tartaric acid and phosphoric acid.The example of basifier comprises arginine, lysine, histidine, meglumine, Magnesiumaluminumsilicate, magnesium aluminometasilicate or basic mineral, as NaHCO 3, CaCO 3, MgCO 3, KH 2pO 4, K 2hPO 3, and tricalcium phosphate etc., preferred NaHCO 3, CaCO 3, MgCO 3or its mixture.
Stabilizing agent can be selected according to the character of active constituents of medicine, and the consumption of the stabilizing agent adopted can for 0.01wt% to 10wt% based on the total amount of selected active constituents of medicine.
Lubricant can be selected from the group be made up of as calcium stearate and magnesium stearate, Pulvis Talci, silica sol, fatty acid cane sugar ester, hydrogenated vegetable oil, high melting-point wax, fatty acid glyceride, glycerol two behenate (glycerol dibehenate) and composition thereof stearic acid, metallic stearate, and the consumption of the lubricant adopted can be in about 0.02wt% to 5wt% based on tablet total weight amount, in the scope of preferred about 0.3wt% to 3wt%.
Coloring agent can be selected from by red iron oxide pigment, yellow iron oxide pigment, titanium dioxide, blue No. 1, blue No. 2, and composition thereof the group that forms, and the consumption of the coloring agent adopted can be in about 0.001wt% to 2wt% based on tablet total weight amount, in the scope of preferred about 0.01wt% to 1.5wt%.
Compound formulation of the present invention comprises multiple MUST, and have thus very fast dissolution velocity and do not experience initial dissolution rate reduce.Usually, traditional hard capsule preparation needs the disintegration time of capsule, therefore there is the shortcoming of the deviation increase of dissolving test result because initial dissolution rate slows down (in 15min).Therefore, if the medicine that compound formulation comprises needs quick absorption rate, such as, the time (T of the maximum drug level of 1 to 2h maximum), the identical bioequivalence expecting compound formulation single dose form may be difficult to.But compound formulation of the present invention comprises multiple small size and can the tablet of simultaneously disintegrate rapidly of having, and therefore there is not the delay of initial dissolution rate.
Therefore, one or more active component of compound formulation of the present invention discharge medicine immediately, one or more active component have the external initial dissolution rate of in administration 5min 30% or higher, and in administration 10min 80% or higher external initial dissolution rate (with reference to Fig. 3 to Fig. 5).
In addition, compound formulation of the present invention separates often kind of active component completely, guarantees the rate of dissolution of improvement and good stability when long term storage.This favourable effect can strengthen further by MUST coating.Therefore, MUST of the present invention can make it any possible interaction that physical property prevents between two or more active component with the coating of polymeric film coat.
Any traditional polymer that can form film coating may be used in film coat of the present invention (film coatings, film coating layer).Concrete example comprise water-soluble polymer as polyvinyl alcohol, hydroxyethyl-cellulose, hydroxypropyl emthylcellulose, polyvinylpyrrolidone, and composition thereof; Insoluble polymer as Hydroxypropyl Methyl Cellulose Phthalate (HPMCP), polyvinyl acetate (such as, sR30D), [copolymer (such as, e.g., to gather (ethyl acrylate-methyl methacrylate) for water-insoluble polymethacrylate copolymer nE30D) copolymer (such as, to gather (ethyl acrylate-methyl methacrylate-trimethylaminoethyl group methacrylate chloride) rSPO) etc.], ethyl cellulose, cellulose esters, cellulose ether, cellulose-acrylate, cellulose diacrylate, cellulose iii acrylate, cellulose acetate, cellulose diacetate, cellulosic triacetate, and composition thereof, but to be not limited thereto.
The use of this polymer is not only played use separated from one another for active component, and play allow to be formed in same capsule have different rate of dissolution (such as, instant/slow release or immediately/casing) MUST.In this case, MUST coated polymer, then can according to ratio filling needed for drug design person anticipation to regulate the rate of dissolution between medicine groups between same medicine group or different.This favourable effect makes it to become possibility as the MUST in the present invention by adopting multiple micro tablet sheet.
The amount of polymer can provide according to effective pattern through overregulating has suitable size and the tablet of rate of dissolution, and this is preferably about 1wt% to 50wt%, more preferably from about 1wt% to 20wt% based on tablet total weight amount.Each tablet separates completely, and forms discrete dosages form, prevents any interaction between these tablets.In addition, in the analysis of the stability of active component prepared in accordance with the present invention, by analyzing traditional method replacement any specific process for this reason of single medicine, be just enough to the stability analyzing each tablet comprised in capsule.
In addition, the invention provides a kind of method for the preparation of hard capsule compound formulation, preparation that it comprises the steps: (1) comprises the MUST of active constituents of medicine; (2) multiple MUST is encapsulated in hard capsule makes hard capsule compound formulation comprise two or more active constituents of medicine.This method can further include the additional step of step (1) the period polymeric film coating MUST at said method.
Hereinafter, the present invention is more specifically described by following examples, but these are all provide for illustration of object, and the present invention is not limited to this.
Embodiment 1: the preparation of compound formulation I
-levocetirizine layer-
-montelukast layer-
Tablet layer containing levocetirizine (levocetirizine) is prepared as following.By levocetirizine dihydrochloride, (BASF), microcrystalline Cellulose, citric acid, cross-linking sodium carboxymethyl cellulose, light anhydrous silicic acid and Magnesium Stearate mix, and use the tablet machine with die diameter 2.0mm to be pressed into tablet in the mixture of gained subsequently, and obtain 10 MUST, wherein every tablet has the weight of 8.3mg, the thickness of about 2.0mm, and the cylinder height of 1.3mm.
In addition, coating solution is by inciting somebody to action y-1-7000 is dissolved in distilled water and prepares, and coating solution painting is imposed on the above obtained MUST containing levocetirizine.The gross weight of 10 MUST obtained like this is 85mg, and levocetirizine gross weight is wherein 5mg.
Meanwhile, the tablet layer containing montelukast (montelukast) is prepared as follows.Menglusitena, PEARLITOL 25C, microcrystalline Cellulose, light anhydrous silicic acid, hydroxypropyl cellulose, sodium starch glycollate and magnesium stearate are carried out sieving and mixing, and use the tablet machine with die diameter 2.0mm to be pressed into tablet in the mixture of gained subsequently, and obtain 20 MUST, wherein every tablet has the weight of 8.3mg, thickness is about 2.0mm, and the cylinder height of 1.3mm.
In addition, coating solution is prepared by hypromellose, hydroxypropyl cellulose, titanium dioxide, red iron oxide and yellow iron oxide being dissolved in distilled water, and coating solution painting is imposed on the MUST containing montelukast of above preparation.The gross weight of 20 MUST of such acquisition is 170mg, and the gross weight of montelukast is wherein 10mg.
The different MUST of this two or more preparation, 10, containing MUST and 20 MUST containing montelukast of levocetirizine, are filled in the capsule body of No. 1 hard capsule made with main gelatin the hard capsule preparation produced containing 10mg montelukast and 5mg levocetirizine.
Embodiment 2: the preparation of compound formulation II
-ambroxol layer-
-levodropropizine layer-
Tablet layer containing ambroxol (ambroxol) is prepared as follows.Ambroxol Hydrochloride, lactose hydrous and pregelatinized Starch being mixed together, add by PVP K-30 being dissolved in the adhesive solution prepared in distilled water, and mixture carrying out wet granulation.Add light anhydrous silicic acid and magnesium stearate wherein, and use the tablet machine with die diameter 2.0mm that mixture is pressed into tablet, and obtain 10 MUST, wherein each tablet has the weight of 7.8mg and thickness is about 2.0mm, and cylinder height is 1.3mm.The gross weight of 10 MUST obtained like this is 78mg, and the gross weight of Ambroxol Hydrochloride is wherein 30mg.
Meanwhile, the tablet layer containing levodropropizine (levodropropizine) is prepared as follows.Levodropropizine, lactose hydrous, microcrystalline Cellulose, sodium starch glycollate and magnesium stearate are carried out sieving and mixing, and use the tablet machine with die diameter 2.0mm to be pressed into tablet in the mixture of gained subsequently, and obtain 20 MUST, wherein every tablet has the weight of 8.0mg, thickness is about 2.0mm, and the cylinder height of 1.4mm.The gross weight of 20 thus obtained MUST is 160mg, and the gross weight of levodropropizine is wherein 60mg.
These the two kinds of different MUST more than prepared, 10, containing MUST and 20 MUST containing levodropropizine of Ambroxol Hydrochloride, are filled in the capsule body of No. 1 hard capsule made with main gelatin the hard capsule preparation produced containing 30mg Ambroxol Hydrochloride and 60mg levodropropizine.
Embodiment 3: the preparation of compound formulation III
-losartan layer-
-amlodipine layer-
Tablet layer containing losartan (losartan) is prepared as follows.By Losartan Potassium, (BASF), copolyvidone, cross-linking sodium carboxymethyl cellulose, light anhydrous silicic acid and magnesium stearate are mixed together, and use the tablet machine with die diameter 2.0mm to be pressed into tablet in mixture subsequently, and obtain 12 MUST, wherein each tablet has the weight of 8.3mg and thickness is about 2.0mm, and cylinder height is 1.2mm.
In addition, coating solution is by inciting somebody to action y-1-7000 is dissolved in distilled water and prepares, and coating solution painting is imposed on the above obtained MUST containing losartan.The gross weight of 12 MUST obtained like this is 102mg, and losartan gross weight is wherein 50mg.
Meanwhile, the tablet layer containing amlodipine is prepared as follows.By amlodipine d-camphorsulfonic acid (amlodipine Camsylate, Amlodipine camsylate), mannitol, microcrystalline Cellulose, sodium starch glycollate, hydroxypropyl cellulose and magnesium stearate carry out sieving and mixing, and use the tablet machine with die diameter 2.0mm to be pressed into tablet in the mixture of gained subsequently, and obtain 12 MUST, wherein every tablet has the weight of 8.3mg, thickness is about 2.0mm, and the cylinder height of 1.3mm.
In addition, coating solution is by inciting somebody to action y-1-7000 is dissolved in distilled water and prepares, and coating solution painting is imposed on the MUST containing amlodipine of above preparation.The gross weight of 12 MUSTs of such acquisition is 102mg, and the gross weight of amlodipine is wherein 10mg.
The different MUSTs of this two or more preparation, 12, containing MUST and 12 MUST containing amlodipine of losartan, are filled in the capsule body of No. 2 hard capsules made with main gelatin the hard capsule preparation produced containing 50mg losartan and 10mg amlodipine.
Embodiment 4: the preparation of compound formulation IV
-Rosuvastatin layer-
-aspirin layer-
Tablet layer containing Rosuvastatin (rosuvastatin) is prepared as follows.Cut down statin calcium, lactose hydrous, microcrystalline Cellulose, polyvinylpolypyrrolidone and magnesium stearate by relaxing to be mixed together, and use the tablet machine with die diameter 2.0mm to be pressed into tablet in mixture subsequently, and obtain 10 MUST, wherein each tablet has the weight of 8.3mg, thickness is about 2.0mm, and the cylinder height of 1.3mm.
In addition, coating solution is by inciting somebody to action y-1-7000 is dissolved in distilled water and prepares, and coating solution painting is imposed on the above obtained MUST containing Rosuvastatin.The gross weight of 10 MUST obtained like this is 86mg, and Rosuvastatin gross weight is wherein 10mg.
Meanwhile, the tablet layer containing aspirin is prepared as follows.Aspirin, microcrystalline Cellulose, pregelatinized Starch and light anhydrous silicic acid are mixed.Stearic acid is added as lubricant in obtained mixture, and use the tablet machine with die diameter 2.0mm to be pressed into tablet in the mixture of gained subsequently, and obtain 20 MUST, wherein every tablet has the weight of 7.05mg, thickness is about 2.0mm, and the cylinder height of 1.2mm.
In addition, coating solution by preparing in the mixed solvent that Hydroxypropyl Methyl Cellulose Phthalate, titanium dioxide and acetylated monoglyceride is dissolved in ethanol and acetone, and coating solution is coated with impose on above preparation containing on the MUST of aspirin.The gross weight of 20 MUST of such acquisition is 160mg, and the gross weight of aspirin is wherein 100mg.
These the two kinds of different MUST more than prepared, 10, containing MUST and 20 MUST containing aspirin of Rosuvastatin, are filled in the capsule body of No. 1 hard capsule made with main gelatin the hard capsule preparation produced containing 10mg Rosuvastatin and 100mg aspirin.
Embodiment 5: the preparation of compound formulation V
-clopidogrel layer-
-aspirin layer-
Tablet layer containing clopidogrel (clopidogrel) is prepared as follows.The sucrose ester of clopidogrel hydrogenesulphate, PEARLITOL 25C, low-substituted hydroxypropyl cellulose and fatty acid is carried out sieving and being mixed together, and use the tablet machine with die diameter 2.0mm to be pressed into tablet in mixture subsequently, and obtain 20 MUST, wherein each tablet has the weight of 8.0mg, thickness is about 2.0mm, and the cylinder height of 1.3mm.
In addition, coating solution is by inciting somebody to action 32K-14834 is dissolved in distilled water and prepares, and coating solution painting imposes on the above obtained MUST containing clopidogrel.The gross weight of 20 MUST obtained like this is 164mg, and clopidogrel gross weight is wherein 75mg.
Meanwhile, the layer containing aspirin is prepared as follows.Aspirin, microcrystalline Cellulose, pregelatinized Starch and light anhydrous silicic acid are mixed.Stearic acid is added as lubricant in obtained mixture, and use the tablet machine with die diameter 2.0mm to be pressed into tablet in the mixture of gained subsequently, and obtain 20 MUST, wherein every tablet has the weight of 7.05mg, thickness is about 2.0mm, and the cylinder height of 1.2mm.
In addition, coating solution by preparing in the mixed solvent that Hydroxypropyl Methyl Cellulose Phthalate, titanium dioxide and acetylated monoglyceride is dissolved in ethanol and acetone, and coating solution is coated with impose on above preparation containing on the MUST of aspirin.The gross weight of 20 MUST of such acquisition is 160mg, and the gross weight of aspirin is wherein 100mg.
These the two kinds of different MUST more than prepared, 20, containing MUST and 20 MUST containing aspirin of clopidogrel, are filled in the capsule body of No. 1 hard capsule made with main gelatin the hard capsule preparation produced containing 75mg clopidogrel and 100mg aspirin.
Comparative examples (comparing embodiment) 1: the preparation of compound formulation VI
-levocetirizine layer-
-montelukast layer-
Tablet layer containing levocetirizine is prepared as following.By levocetirizine dihydrochloride, (BASF), microcrystalline Cellulose, citric acid, cross-linking sodium carboxymethyl cellulose, light anhydrous silicic acid and Magnesium Stearate mix, and use the tablet machine with die diameter 5.0mm to be pressed into tablet in the mixture of gained subsequently.Then, by inciting somebody to action the coating solution that Y-1-7000 to be dissolved in distilled water preparation is coated with to impose on tablet and generates levocetirizine tablet.The tablet total weight amount obtained like this is 85mg, and levocetirizine gross weight is wherein 5mg.
Meanwhile, the tablet layer containing montelukast is prepared as follows.Menglusitena, PEARLITOL 25C, microcrystalline Cellulose, light anhydrous silicic acid, hydroxypropyl cellulose, sodium starch glycollate and magnesium stearate are carried out sieving and mixing, and use the tablet machine with die diameter 5.0mm to be pressed into tablet in the mixture of gained subsequently, and obtain two tablets.In addition, coating solution passes through hypromellose, hydroxypropyl cellulose, titanium dioxide, and red iron oxide and yellow iron oxide are dissolved in distilled water to be prepared, and coating solution painting is imposed on above tablet and generate montelukast tablet.The gross weight of the tablet of such acquisition is 170mg, and the gross weight of montelukast is wherein 10mg.
These the two kinds of different tablets more than prepared, 1 levocetirizine tablet and 2 montelukast tablets, be filled in the capsule body of No. 1 hard capsule made with main gelatin the hard capsule preparation produced containing 5mg levocetirizine and 10mg montelukast.
Comparative examples 2: the preparation of compound formulation VII
-ambroxol layer-
-levodropropizine layer-
Tablet layer containing ambroxol is prepared as following.By Ambroxol Hydrochloride, lactose hydrous and pregelatinized Starch mixing, add by PVP K-30 being dissolved in the adhesive solution prepared in distilled water, and subsequently by the mixture wet granulation of gained.Add light anhydrous silicic acid and magnesium stearate wherein, and use the tablet machine with die diameter 5.0mm to be pressed into tablet in mixture.The tablet total weight amount obtained thus is 78mg, and Ambroxol Hydrochloride gross weight is wherein 30mg.
Meanwhile, the tablet layer containing levodropropizine is prepared as follows.Levodropropizine, lactose hydrous, microcrystalline Cellulose, sodium starch glycollate and magnesium stearate are carried out sieving and mixing, and uses the tablet machine with die diameter 5.0mm to be pressed into tablet in the mixture of gained subsequently, and obtain two tablets.The gross weight of the tablet of such acquisition is 160mg, and the gross weight of levodropropizine is wherein 60mg.
The different tablets of this two or more preparation, 1 ambroxol tablet and 2 levodropropizine tablets, be filled in the capsule body of No. 1 hard capsule made with main gelatin the hard capsule preparation produced containing 30mg Ambroxol Hydrochloride and 60mg levodropropizine.
Testing example 1: the dissolving test of montelukast and levocetirizine
Montelukast containing preparation in embodiment 1 and comparative examples 1 and the compound formulation of levocetirizine, and be used separately as montelukast and levocetirizine reference drug tablet (MSD, 10mg) and tablet (Korea S-UCB Co., 5mg), uses 6 test containers being used for often kind of medicine to carry out medicine dissolution test under the following conditions.The results are shown in table 1, and Fig. 3 and as in Fig. 4.
< test condition >
-dissolve medium:
For montelukast=0.5% sodium lauryl sulfate (SLS) solution, 900mL
For levocetirizine=distilled water, 900mL
-dissolve test macro: flat oar, 75rpm
-temperature: 37 DEG C
< analysis condition-Simultaneously test montelukast and levocetirizine >
-pillar: the rustless steel pillar of filling 5 μm of octadecylsilane base silica gel is used for liquid chromatograph (Inertsil C8,4.6 × 150mm, 5 μm)
-mobile phase: 0.025M potassium dihydrogen phosphate (pH6.6), acetonitrile (40:60, v/v)
-detector: ultraviolet spectrophotometer (225nm)
-flow velocity: 1.0mL/min
-note sample volume: 10 μ L
-column temperature: 45 DEG C
[table 1]
As shown in table 1 and Fig. 3 and Fig. 4, the compound formulation comprising MUST of preparation in embodiment 1 goes out much higher initial dissolution rate (in 10 minutes) compared to the formulations display of comparative examples 1 containing conventional tablet, is even similar to reference to medicine, tablet (montelukast) and tablet (levocetirizine).
In addition, the montelukast of embodiment 1 and the dissolving test result of levocetirizine show significantly lower standard deviation value than the result that the dissolving of comparative examples 1 is tested, and therefore can expect that body absorption rate variation is less by compound formulation of the present invention.Therefore, this also can expect that the hard capsule compound formulation comprising MUST for the present invention will be easier to and its reference drug with bioequivalent.
Testing example 2: the dissolving test of ambroxol
The compound formulation containing ambroxol and levodropropizine containing preparation in embodiment 2 and comparative examples 2, and be used as ambroxol reference drug tablet (Boehringer Ingelheim, 30mg), uses 6 test containers being used for often kind of medicine to carry out medicine dissolution test under the following conditions.The results are shown in table 2, and in Fig. 5.
< test condition >
-dissolve medium: pH1.2 simulated gastric fluid, 900mL
-dissolve test macro: flat oar, 50rpm
-temperature: 37 DEG C
< analysis condition-ambroxol >
-pillar: the rustless steel pillar of filling 5 μm of octadecylsilane base silica gel is used for liquid chromatograph (Waters ODS-2,4.6mm × 50mm, 5 μm)
-mobile phase: 0.05M potassium dihydrogen phosphate (using phosphoric acid to be adjusted to pH3.0), methanol (88:12, v/v)
-detector: ultraviolet spectrophotometer (254nm)
-flow velocity: 1.0mL/min
-note sample volume: 10 μ L
-column temperature: 30 DEG C
[table 2]
As shown in table 2 and Fig. 5, in embodiment 2, presenting containing the compound formulation of MUST of preparation fills the much higher initial dissolution rate (in 10 minutes) of the preparation of conventional tablet and much smaller standard deviation changing value than comparative examples 2.
Therefore, this it is expected to, if ambroxol, its initial dissolution rate is considered to critical in its given T of 0.25 ~ 1 hour maximum, contain the form preparation of the hard capsule compound formulation of MUST with the present invention, then will be easier to it with reference to medicine for compound formulation of the present invention, tablet is bioequivalence, and also expects that body absorption rate variation is less.
Testing example 3: the absorption test of montelukast and levocetirizine
Compound formulation containing montelukast and levocetirizine prepared by embodiment 1, and respectively as the reference drug of montelukast and levocetirizine tablet 10mg and tablet 5mg, is administered orally in test animal and carries out bioavailability test under the following conditions.
Test animal is healthy, male, 20 months large beasle dogs, body weight 12 ± 2kg, and each fractions tested joins 5 Canis familiaris L.s.These Canis familiaris L.s are positioned in cage, allow it freely use business dog feed (every day 400 grams), then one period of 14 hours of fasting before experiment.Canis familiaris L. is divided into the two groups: 1st group (embodiment 1) and the 2nd group ( tablet+ tablet).The corresponding preparation of each Canis familiaris L. oral administration, and force to give 40mg water.Blood sample (2mL) adopt there is anticoagulant (1,000IU/mL, heparin 5 μ L) pipe after oral administration 0 (initially), 0.25,0.5,1,2,3,4,8,10,24 and 48h time from the beginning venous collection.Whole blood sample centrifugal (12000rpm, 2 minutes, Eppendorf) to blood plasma, and at-20 DEG C splendid attire in refrigerator to carry out subsequent analysis by the LC-MS under following condition to each sample:
Pillar: Halo C18 (2.1 × 50mm, 2.7 μm)
Mobile phase: methanol, 10mM ammonium formate (85:15, v/v)
Injection rate: 10 μ L
Detect: Turbo ion spray ionisation pattern (positive electricity)
C maxand T maxavailable from plasma concentration relative to time graph, and the AUC use curve from 0 to 24h after administration calculates according to ladder type rule.Result is as shown in table 3, Fig. 6 and Fig. 7.
[table 3]
As shown in table 3 and Fig. 6 and Fig. 7, the compound formulation of embodiment 1 has takes two kinds of unitary agents with reference to the equal or better bioavailability of tablet than simultaneously.
Cause montelukast and levocetirizine and its with reference to medicine according to the compound formulation of embodiment 1, tablet and tablet, has similar AUC and C maximumvalue, and demonstrate T ? greatlyvalue does not postpone, but small T maximumvalue.

Claims (16)

1. one kind comprises the hard capsule compound formulation of two or more active constituents of medicine, wherein, often kind of active constituents of medicine to be contained in the spherical tablet of multiple-unit (MUST) and the multiple described MUST of often kind of active constituents of medicine is encapsulated in described hard capsule.
2. hard capsule compound formulation according to claim 1, wherein, each MUST has the ratio of diameter that scope is 1:0.7 to 1:1.3 and thickness.
3. hard capsule compound formulation according to claim 1, wherein, the diameter of each MUST is less than or equal to 1/2 of described hard capsule internal diameter.
4. hard capsule compound formulation according to claim 1, wherein, each MUST has the diameter that scope is 1mm to 4mm.
5. hard capsule compound formulation according to claim 1, wherein, each MUST has the ratio of thickness that scope is 1:0.3 to 1:0.9 and cylinder height.
6. hard capsule compound formulation according to claim 5, wherein, the scope of the ratio of described thickness and cylinder height is 1:0.5 to 1:0.8.
7. hard capsule compound formulation according to claim 1, comprises 4 to 40 MUST of often kind of active constituents of medicine.
8. hard capsule compound formulation according to claim 1, wherein, described hard capsule is No. 0, hard capsule, No. 1, hard capsule, No. 2, hard capsule, No. 3, hard capsule or No. 4, hard capsule.
9. hard capsule compound formulation according to claim 1, wherein, often kind of active constituents of medicine is selected from the group be made up of the following: levocetirizine, montelukast, ambroxol, levodropropizine, losartan, Irb, amlodipine, Rosuvastatin, atorvastatin, aspirin, clopidogrel, aceclofenac, eperisone, esomeprazole, naproxen and their pharmaceutical salts.
10. hard capsule compound formulation according to claim 1, wherein, each MUST comprises medical additive.
11. hard capsule compound formulations according to claim 10, wherein, described medical additive is selected from the group be made up of medicinal diluent, disintegrating agent, binding agent, stabilizing agent, lubricant, coloring agent and their mixture.
12. hard capsule compound formulations according to claim 1, wherein, each MUST is coated with polymeric film coat.
13. hard capsule compound formulations according to claim 1, wherein, described in one or more, active constituents of medicine discharges immediately.
14. hard capsule compound formulations according to claim 13, wherein, active constituents of medicine described in one or more to have from administration in 5 minutes 30% or higher external initial dissolution rate and from administration in 10 minutes 80% or higher external initial dissolution rate.
15. 1 kinds of methods for the preparation of hard capsule compound formulation according to claim 1, described method comprises:
(1) preparation comprises the MUST of active constituents of medicine; And
(2) multiple described MUST be encapsulated in described hard capsule and make described hard capsule compound formulation comprise two or more active constituents of medicine.
16. methods according to claim 15, described method is included in step (1) period polymeric film further and applies each MUST.
CN201380019865.6A 2012-04-13 2013-04-12 Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same Pending CN104220050A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910062530.1A CN110051642B (en) 2012-04-13 2013-04-12 Complex formulation comprising multi-unit spherical tablet (MUST) encapsulated in hard capsule and method for preparing the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2012-0038594 2012-04-13
KR1020120038594A KR101378973B1 (en) 2012-04-13 2012-04-13 Composite formulation comprising multi-unit spheroidal tablet(must) encapsulated in a hard capsule and method for preparing the same
PCT/KR2013/003099 WO2013154390A1 (en) 2012-04-13 2013-04-12 Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910062530.1A Division CN110051642B (en) 2012-04-13 2013-04-12 Complex formulation comprising multi-unit spherical tablet (MUST) encapsulated in hard capsule and method for preparing the same

Publications (1)

Publication Number Publication Date
CN104220050A true CN104220050A (en) 2014-12-17

Family

ID=49327885

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910062530.1A Active CN110051642B (en) 2012-04-13 2013-04-12 Complex formulation comprising multi-unit spherical tablet (MUST) encapsulated in hard capsule and method for preparing the same
CN201380019865.6A Pending CN104220050A (en) 2012-04-13 2013-04-12 Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910062530.1A Active CN110051642B (en) 2012-04-13 2013-04-12 Complex formulation comprising multi-unit spherical tablet (MUST) encapsulated in hard capsule and method for preparing the same

Country Status (22)

Country Link
US (1) US20150098992A1 (en)
EP (1) EP2836207B1 (en)
JP (1) JP6129295B2 (en)
KR (1) KR101378973B1 (en)
CN (2) CN110051642B (en)
BR (1) BR112014024964B1 (en)
CL (1) CL2014002717A1 (en)
CO (1) CO7131367A2 (en)
ES (1) ES2778864T3 (en)
HK (1) HK1204959A1 (en)
MX (1) MX354328B (en)
MY (1) MY171703A (en)
PE (1) PE20142035A1 (en)
PH (1) PH12014502271A1 (en)
PL (1) PL2836207T3 (en)
PT (1) PT2836207T (en)
RU (1) RU2014145557A (en)
SG (1) SG11201406298RA (en)
TW (1) TWI544936B (en)
UA (1) UA116102C2 (en)
WO (1) WO2013154390A1 (en)
ZA (1) ZA201408285B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032020A (en) * 2017-09-28 2020-04-17 韩美药品株式会社 Multi-unit spherical tablet medicine composition containing esomeprazole and spherical pharmaceutically acceptable salt and preparation method of medicine composition

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101910901B1 (en) * 2013-11-29 2018-10-24 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
EP3209285A1 (en) * 2014-10-21 2017-08-30 Reckitt Benckiser LLC Pharmaceutical capsule containing at least two tablets
CN108156807A (en) * 2015-06-30 2018-06-12 韩美药品株式会社 Medicine compound preparation containing Amlodipine, Losartan and Rosuvastatin
BE1023011B1 (en) * 2015-08-05 2016-11-04 Nordic Specialty Pharma Bvba Acetylsalicylic acid tablet with immediate release
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
KR101625344B1 (en) * 2015-12-21 2016-06-08 주식회사 유영제약 Pharmaceutical compositions comprising celecoxib and duloxetine
PL3222279T3 (en) 2016-03-21 2022-05-09 Invest Bielany Spółka Z Ograniczoną Odpowiedzialnością Oral pharmaceutical formulation of montelukast and levocetirizine and method for its production
KR101920996B1 (en) * 2017-04-26 2018-11-22 알보젠코리아 주식회사 A Complex Formulation Comprising HMG-CoA Reductase Inhibitor and Calcium Channel Blocker
KR102026982B1 (en) * 2018-02-02 2019-09-30 주식회사 씨티씨바이오 Capsule filling apparatus
WO2020204609A1 (en) 2019-04-02 2020-10-08 한미약품 주식회사 Pharmaceutical composition comprising esomeprazole or pharmaceutically acceptable salt thereof and having double-release profile
KR20210052281A (en) * 2019-10-29 2021-05-10 신에쓰 가가꾸 고교 가부시끼가이샤 Capsule filling composition, method of producing capsule formulation with the use of capsule filling composition, and capsule formulation
US20210275531A1 (en) * 2020-03-04 2021-09-09 VK Research Associates Inc Phosphodiesterase-5 inhibitor combinations, methods of making, and methods of use thereof
CN116134048A (en) 2020-04-17 2023-05-16 Hb生物科技有限公司 Compositions and methods for treating neuropsychiatric disorders
EP4085903A1 (en) * 2021-05-07 2022-11-09 Midas Pharma GmbH Mini-tablet containing losartan for pediatric applications
WO2023021480A1 (en) * 2021-08-19 2023-02-23 Clexio Biosciences Ltd. Method of treating parkinson's disease
KR20240045586A (en) 2022-09-30 2024-04-08 주식회사 제뉴원사이언스 Bilayer tablets with enhanced stability comprising levocetirizine or pharmaceutically acceptable salt thereof and montelukast or pharmaceutically acceptable salt thereof and method for preparing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1462098A1 (en) * 2003-03-03 2004-09-29 SPRL Franpharma Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin
WO2007078110A1 (en) * 2006-01-03 2007-07-12 Neomedics Co., Ltd. Pharmaceutical formulation containing amlodipine and aspirin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4773907A (en) * 1982-12-20 1988-09-27 Alza Corporation Primary delivery system comprising secondary dosage form
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
SE9600070D0 (en) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
GB9711962D0 (en) * 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
JP2000128779A (en) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc Controlled release medicine type preparation
DE19901683B4 (en) * 1999-01-18 2005-07-21 Grünenthal GmbH Controlled-release analgesic
CA2391707C (en) * 1999-07-30 2010-05-11 Smithkline Beecham Plc Multi-component pharmaceutical dosage form
BR0312445A (en) * 2002-06-07 2005-05-10 Ranbaxy Lab Ltd Multi-unit systems for delivery of modified-release drug
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US9233075B2 (en) * 2005-08-09 2016-01-12 Metacure Limited Satiety
PE20080661A1 (en) * 2006-09-12 2008-06-12 Glaxo Group Ltd PHARMACEUTICAL COMPOSITION INCLUDING AN INHIBITOR OF FACTOR Xa
KR100888131B1 (en) * 2006-10-10 2009-03-11 한올제약주식회사 Combination preparation for Cardiovascular disease therapy by Chronotherapy theory.
US20100239665A1 (en) * 2007-05-01 2010-09-23 Ivan Coulter Pharmaceutical nimodipine compositions
KR20090091084A (en) * 2008-02-22 2009-08-26 한올제약주식회사 Controlled-release pharmaceutical formulation
EP2255797A4 (en) * 2008-02-22 2011-09-07 Hanall Biopharma Co Ltd Composite preparation
HUE028919T2 (en) * 2008-03-28 2017-01-30 Ferrer Int Capsule for the prevention of cardiovascular diseases
TR201005325A2 (en) * 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Pharmaceutical formulations containing atorvastatin and aspirin
KR101298788B1 (en) * 2011-03-15 2013-08-22 보령제약 주식회사 A combined formulation with improved stability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1462098A1 (en) * 2003-03-03 2004-09-29 SPRL Franpharma Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin
WO2007078110A1 (en) * 2006-01-03 2007-07-12 Neomedics Co., Ltd. Pharmaceutical formulation containing amlodipine and aspirin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032020A (en) * 2017-09-28 2020-04-17 韩美药品株式会社 Multi-unit spherical tablet medicine composition containing esomeprazole and spherical pharmaceutically acceptable salt and preparation method of medicine composition

Also Published As

Publication number Publication date
MY171703A (en) 2019-10-23
RU2014145557A (en) 2016-06-10
PH12014502271B1 (en) 2014-12-10
JP2015517998A (en) 2015-06-25
ES2778864T3 (en) 2020-08-12
WO2013154390A1 (en) 2013-10-17
TWI544936B (en) 2016-08-11
US20150098992A1 (en) 2015-04-09
ZA201408285B (en) 2016-09-28
EP2836207A4 (en) 2015-08-19
BR112014024964A8 (en) 2021-06-15
PL2836207T3 (en) 2020-07-27
CL2014002717A1 (en) 2015-01-09
MX2014012144A (en) 2014-12-05
SG11201406298RA (en) 2014-11-27
PT2836207T (en) 2020-03-26
CN110051642A (en) 2019-07-26
KR101378973B1 (en) 2014-03-28
TW201345568A (en) 2013-11-16
BR112014024964B1 (en) 2022-03-15
CO7131367A2 (en) 2014-12-01
MX354328B (en) 2018-02-27
JP6129295B2 (en) 2017-05-17
CN110051642B (en) 2021-12-31
PH12014502271A1 (en) 2014-12-10
PE20142035A1 (en) 2014-12-24
UA116102C2 (en) 2018-02-12
BR112014024964A2 (en) 2017-06-20
EP2836207A1 (en) 2015-02-18
EP2836207B1 (en) 2020-02-19
HK1204959A1 (en) 2015-12-11
KR20130115864A (en) 2013-10-22

Similar Documents

Publication Publication Date Title
CN104220050A (en) Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same
US9220704B2 (en) Composite formulation comprising a tablet encapsulated in a hard capsule
US20080286344A1 (en) Solid form
CA2914365C (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
TW200427448A (en) Controlled release preparations comprising tramadol and topiramate
EP2200591A2 (en) Controlled release pharmaceutical dosage forms of trimetazidine
KR20030009440A (en) Composition
WO2011146611A1 (en) Modified gastroretentive drug delivery system for amine drugs
JP2014530250A (en) Stabilized eperisone pharmaceutical composition and sustained-release preparation containing the same
WO2008140461A1 (en) Solid form
CA2840765A1 (en) Multilayered dosage form
US20240041777A1 (en) Pharmaceutical capsule containing at least two tablets
WO2012029838A1 (en) Orally disintegrating tablet
US20100291209A1 (en) Organic compounds
AU2013213317B2 (en) In-situ multilayered tablet technology
CN102526049A (en) Compound diclofenac sodium slow-release preparation and preparation method thereof
JP6106359B2 (en) Solid formulation containing loxoprofen sodium and vitamin B1
EP2848260B1 (en) Novel formulations of thiocolchicoside

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1204959

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141217

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1204959

Country of ref document: HK